Background: It remains unclear whether overall degree of immunosuppression or spe-
| INTRODUCTION
Changes in immunosuppressive protocols applied in transplantation medicine have led to decreased allograft rejection rates. Currently, triple immunosuppressive regimens are mostly applied, including prednisolone (Pred), a calcineurin inhibitor (tacrolimus [TAC] , cyclosporine [CsA] ), and an antimetabolite (mycophenolic acid, mycophenolate mofetil [MMF] ). These drugs act on different phases of the immune proliferative steps, thereby inhibiting the immune response in a multi-hit model.
With these new, more potent therapeutic strategies, other problems have emerged in the field of transplantation, such as viral infections with BK polyomavirus (BKPyV). BKPyV can cause hemorrhagic cystitis in patients after bone marrow transplantation and BKPyVassociated nephropathy (BKVAN) in renal transplant recipients (RTR). 1, 2 In the last decades, an increase in BKVAN in up to 10% of RTR has been observed, with an associated risk of losing the allograft of up to 50%.
2 Multiple risk factors have been identified, including human leukocyte antigen (HLA) mismatching, donor age, deceased donor status, male gender, viral co-infections, and anti-rejection treatment with anti-thymocyte globulin or intravenous immunoglobulin. [3] [4] [5] [6] Currently, no effective antiviral therapy is available for treatment of BKPyV replication. Reduction in immunosuppression, eg, reduction in MMF and/or calcineurin inhibitor, is commonly regarded as the best method to control BKPyV replication, but increases the risk of allograft rejection.
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Because immunosuppressants are regarded as important risk factors in the development of BKPyV-related pathology, the question remains if one immunosuppressive agent or the total immunosuppressive load is responsible for this increased risk of developing BKVAN.
The aim of this study was to investigate the isolated effect of the calcineurin inhibitor CsA, the antimetabolite MMF (as mycophenolate sodium [MPS] ), and mammalian target of rapamycin (mTOR) inhibitor everolimus (EVL) on BKPyV replication and on the duration of BKPyV replication, and to study the clinical applicability of each of these individual agents as dual immunosuppressive therapy (with Pred), as a possible alternative for high-risk transplant patients (patients with a high HLA mismatch, older patients, transplantations with a high cold ischemia time). In this study, the incidence of BK viruria, viremia, and BKVAN was studied in a randomized controlled, prospective multicenter trial with 224 de novo RTR receiving dual immunosuppressive therapy consisting of Pred and either CsA, MPS, or EVL. Follow-up of the study was 24 months after renal transplantation. Patients underwent renal biopsy at 6 months and at 24 months.
| PATIENTS AND METHODS

| Patients
Biopsy-proven rejection was treated with methylprednisolone pulses.
Refractory rejection episodes were treated with rabbit anti-thymocyte globulin (5 doses 2.5 mg/kg; Merieux, Lyon, France).
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RTR with no sign of rejection in the protocol biopsy at 6 months after transplantation were randomized into three different treatment 
| BKPyV real-time polymerase chain reaction (RT-PCR)
An internally controlled in-house developed quantitative BKPyV RT-PCR, amplifying a 131 bp of the VP2 gene, with a detection limit of 2 log 10 copies/mL, was used for the detection of BKPyV DNA (Table S1 ).
BK viruria and BK viremia were defined as a concentration of BKPyV >2 log 10 copies/mL in urine and serum, respectively. The term 'return to latency' was defined as a concentration <2 log 10 copies/mL BKPyV in urine subsequent to a positive urine test.
According to the manufacturer's instructions, DNA was extracted 50°C for 2 minutes, 95°C for 10 minutes, followed by 42 cycles of 95°C for 15 seconds, and 60°C for 1 minute.
| Statistics
Statistical analysis was performed using IBM SPSS Statistics 22. Baseline characteristics and incidence of BKPyV infection (viruria, viremia, nephropathy) between the three different treatment groups, primary infections, and reactivations were compared using Chi-square test and ANOVA for categorical variables and continuous variables, respectively.
Statistical analyses were performed based on intention-to-treat population. Longitudinal data were analyzed using generalized estimating equations (GEE) with an exchangeable correlation matrix. Short-term effect (0-6 months) and long-term effect (6-24 months) were analyzed separately. Estimated marginal means (EMM) with 95% confidence intervals from the GEE analyses were plotted in graphs. Biopsy-proven acute rejection (BPAR) during 24 months was compared using survival analysis with log-rank test. Figures were plotted using Graphpad Prism 5.01 (La Jolla, CA, USA). Two-sided P <.05 were considered significant.
| RESULTS
| Baseline characteristics
In this study, 361 RTR were enrolled, of whom 276 RTR underwent a protocol biopsy at 6 months. Reasons for discontinuation of the study are listed in Figure 1 . Borderline changes and Banff grade 1A, grade 1B, or higher acute rejection, were found in 50 of 276 RTR, and two RTR were excluded because of other complications. In total, 224 RTR were randomized into the three different treatment groups. In patients not randomized at 6 months, the number of deceased donors and the cold ischemia time were significantly higher, compared to patients randomized at 6 months (Table S2 ). In the patients randomized at 6 months, the baseline characteristics between the three different treatment groups did not differ significantly (Table 1) .
In all three research groups together, from 6-24 months, 558
of 896 time-point samples were collected and available for analysis (62.3%). In total, 157 of the 224 randomized RTR (70%) were treated per protocol, completed follow-up, and underwent a renal biopsy at 24 months ( Figure 1 ). Of the 89 RTR assigned to treatment with CsA, 74 (83%) were still treated according to protocol 2 years after transplantation, vs 58 of 96 (60%) RTR in the EVL group and 25 of 39 (64%) RTR in the MPS group. Figure 1 summarizes randomization of patients and reasons for discontinuation of the study protocol.
| Drug exposure
From 0 to 6 months, no differences in mean CsA and MPS AUC 12 hrs in the three treatment groups, randomized at 6 months, were found.
No differences in mean CsA and MPS AUC 12 hrs were found between randomized and not randomized patients at 6 months. In the CsA group, CsA AUC 12 hrs at 6 and 24 months were 3280±971 μg*h/L and 3278±907 μg*h/L, respectively. Mean AUC 12 hrs in the MPS group were 47±20 mg*h/L at 6 months and 49±23 mg*h/L at 24 months. In the EVL group, the mean AUC 12 hrs was 203±21 mg*h/L 1 month after conversion and 159±44 mg*h/L at 24 months. Mean AUC 12 hrs of the CsA, MPS, and EVL group at 6, 7, 12, 18, and 24 months are depicted in Figure S1 . Pred exposure was not measured via AUC. Pred doses at t=6, 7, 12, 18, and 24 are depicted for the three treatment groups in Figure S2 and did not differ among the three groups.
| Primary outcomes BK viruria, viremia, and BKVAN
| BK viruria
Of the 224 patients included, 65 tested positive for BKPyV replication (29.0%). From 0 to 6 months, no differences in BKPyV replication are seen between the three treatment groups. In this period, the incidence of BKPyV replication in urine was 12 (13.5%) in the CsA group, were not randomized (Table S3) . Furthermore, the incidence of viruria between patients treated per protocol and patients who switched from immunosuppression for medical reasons, did not differ significantly in the three treatment groups (Table S4 ).
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| BK viremia and BKVAN
In total, 31 RTR tested positive for BKPyV replication in serum. Incidence of BK viremia before 6 months was 7 (7.9%), 3 (7.7%), and 6 (6.3%) in the CsA, MPS, and EVL group, respectively (P=.90). From 6 to 24 months the incidence of BK viremia in the three groups was 4 (4.5%), 3 (7.7%), and 3 (3.1%) (P=.51). Three patients developed BKVAN. All three patients were treated with MPS (P=.001) (1.3% of the total cohort, 7.7% of MPS). In Table 2 primary outcome of the study from 6 to 24 months is depicted.
The incidence of BK viremia and BKVAN within 24 months was not significantly different between randomized patients (n=224) vs patients excluded at 6 months (n=137) ( Table S3 ) and incidence of BK viremia and BKVAN did not differ between patients treated per protocol and patients who switched from immunosuppression during the study (Table S4) . 
| Longitudinal analysis
GEE analysis of long-term effect (t=6-24 months) was performed on the BKPyV VL in urine (Figure 2 ). Longitudinal EMM of concentration of BKPyV (log 10 copies/mL) in urine from 6 to 24 months is depicted in Figure 2A . (Figure 2A ).
In Figure 2B , the course of BKPyV VLs EMM in urine over 24 months is displayed. BKPyV VL in urine decreased in the CsA group with an EMM from 6 to 24 months of 2.07 to 0.63 log 10 copies/ mL, whereas it remained persistently high in the MPS group with an EMM from 6 to 24 months of 2.20 to 2.43 log 10 copies/mL (P=.05) ( Figure 2B ). This difference became significant after adjustment for donor type, donor age, cytomegalovirus status donor, HLA mismatch (A, B, and DR), with an EMM in the CsA group from 6 to 24 months of 2.26 of 0.86 log 10 copies/mL, and an EMM in the MPS group of 2.46 to 2.66 log 10 copies/mL (P=.03).
In serum, no significant differences in course of BKPyV infection were found.
| Death, graft loss, and BPAR
The combined incidence of death, graft loss, and allograft rejection from 6 to 24 months was 13 (14.6%), 9 (23.1%), and 5 (5.2%) in the CsA, MPS, and EVL group, respectively (P=.001). In total, 8 (9.0%), 8 (20.5%), and 1 (1.0%) BPAR episodes were reported in the CsA, MPS, and EVL group between 6 months and 24 months (Figure 3 , P<.001). These were clinical rejections in 'for cause' biopsies-biopsies on indication-in 100% of the cases. No signs of clinical rejection were found in the 24-month protocol biopsies. The majority of these rejections were Banff type I rejections (Table 3) . No cases of antibody-mediated rejection occurred.
When the sequence of rejection and BKPyV-related pathology is examined, most BKPyV infection episodes are not related to an episode of allograft rejection. No significant differences in incidence of BK viruria or viremia, after an episode of allograft rejection, were found between the three treatment groups (Tables S5 and S6 ). BKVAN was exclusively found in the MPS group. These three cases of BKVAN were in patients who did not experience allograft rejection during their 24-month post-transplantation follow-up.
| Renal function
Estimated glomerular filtration rates (eGFR, MDRD formula) were compared between BK viruria-positive and BK viruria-negative T A B L E 2 Primary outcome BK polyomavirus (BK) replication and BKVAN from 6 to 24 months Although we do not see a significant increase in the incidence of BK viremia in patients treated with MPS compared to CsA and EVL, we did observe an increased incidence of viruria and BKVAN. We therefore hypothesized that BKPyV infection is more severe, with prolonged infection episodes and can more easily progress to BKVAN in this group, which was confirmed by our longitudinal analyses.
| DISCUSSION
It is unclear whether MPS directly affects viral replication of
BKPyV, but it is thought that MPS is an important factor in main- Translating these data to our study is highly speculative, but one of the above-mentioned mechanisms could be involved in the protracted high BKPyV loads in urine measured in the EVL group. Furthermore, treatment with dual immunosuppressive therapy could elicit these viral promoting effects, whereas these effects are obscured by effects of other immunosuppressants in treatment with triple-drug therapy.
However, whether these above-mentioned mechanisms are also operative in BKPyV infection remains unclear, and as we find opposing effects of some agents, further in vitro and in vivo research is needed.
As mentioned, this prospective multicenter, open-label randomized controlled trial offered the opportunity to study the isolated effects of CsA, MPS, and EVL on BKPyV replication. However, the study has some limitations. First, owing to the clinical status, patients with a rejection episode before 6 months were excluded from the study. This group potentially consists of patients who were at increased risk of BKPyV infection, because of the necessity of increased immunosuppression. Still, excluded patients did not have increased frequencies of BKPyV-related pathology compared to randomized patients. Second, in this study, patients were not treated with TAC, which is more frequently used in current immunosuppressive regimens. In multiple studies, the combination of Pred, MPS, and TAC has been associated with a higher risk of BKPyV complications. 15, 18, 34, 35 In this study, we cannot directly compare the effect of CsA and TAC on BKPyV replication. Third, measuring of drug exposure with the AUC is a method that nowadays is less commonly used in the clinic. Unfortunately, we cannot provide trough levels of the drugs. Still, the reported AUC data
give an indication about the actual level of immunosuppression patients received in the three research groups. Last, BKPyV monitoring in urine and serum, and possible therapy adaptations upon BKPyV replication, were not protocolized. However, this fact also minimized interventions and enables the study of long-term VL and viral clearance.
A possible confounding effect of the anti-rejection therapy in the MPS group, causing the BKPyV-related pathology, can be ruled out, as the post-rejection incidence of BKPyV infection is very low, and the incidence of this type of BKPyV infection did not differ among the three treatment groups. Furthermore, methylprednisolone as anti-rejection therapy is not regarded as a risk factor for BKPyV infection or BKVAN, as is demonstrated in several studies and reviews, while maintenance steroid therapy is. [35] [36] [37] However, drug doses of Pred are not higher in the MPS group than in the other treatment groups. A possible confounding effect of maintenance steroid therapy in the development of BKPyV infection and BKVAN is therefore unlikely. Last, a possible confounding effect of the switch of patients to other immunosuppressive T A B L E 3 Summary of efficacy related result from 6 to 24 months medication during this study is also unlikely. Rates of BK viruria, viremia, and BKVAN were compared between the patients treated per protocol and the patients who at some point switched immunosuppression, and showed no significant differences between these subgroups (Table S4 ).
In summary, we can conclude from this study that dual immunosuppressive therapy with MPS+Pred is associated with a prolonged
BKPyV infection period and with a higher incidence of BKVAN, while treatment with CsA+Pred can be regarded as an effective treatment to limit BKPyV replication in the first 2 years post transplantation.
This dual treatment can be done in an immunological low-risk transplantation cohort, without increasing the risk of graft loss or allograft rejection.
